Lexeo Therapeutics

Happy Thanksgiving from Lexeo Therapeutics! We hope everyone enjoys the holiday and has quality time with family & friends.

Team Lexeo was proud to participate in the recent 2024 Walk to End Alzheimer’s in NYC, led by the Alzheimer's Association®. Employees and their families joined hundreds of others to raise awareness about this debilitating disease, and the event helped to raise over $1 million for Alzheimer’s disease research.   Thanks to everyone for getting out to support this critical cause! You can learn more about joining a walk in your hometown here: https://lnkd.in/dr8eB7i

This past weekend, our team was thrilled to participate in the American Heart Association’s annual conference. It was great to interact with leaders in the cardiac community at our Lexeo lounge, learn from scientific sessions and host our first Lexeo-sponsored symposia titled: ‘Getting to the Heart of the Matter: Gene Therapy for Cardiac Diseases’. We look forward to continued engagement with the cardiology community. Learn more about Lexeo’s cardiac programs here: https://lnkd.in/eFbqFviF

November marks Alzheimer’s Awareness month, a time to show support for the more than 6 million Americans currently living with Alzheimer’s disease. Lexeo is investigating several approaches to treat the underlying genetic cause of APOE4-associated Alzheimer’s disease, and we recently released interim data from the Phase 1/2 clinical trial of gene therapy candidate LX1001. You can find more information LX1001, and our approach here: https://lnkd.in/eHeuVbxr

Lexeo is a proud sponsor of this year’s International Congress for Ataxia Research (ICAR) in London. Tomorrow, Dr. Theresa Zesiewicz, Professor of Neurology and Director of the USF Ataxia Research Center, will present preliminary results from the SUNRISE-FA trial, a Lexeo-sponsored phase 1/2 study of LX2006 for Friedreich ataxia (FA) cardiomyopathy. Learn more about LX2006 and our research in FA cardiomyopathy here: https://lnkd.in/exYWF9U7

Today, we are pleased to share our third quarter 2024 financial results and operational highlights. We have made significant progress over the last few months across all our clinical stage programs, including now reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006, and adding Tolga Tanguler to our Board of Directors. Read more in the press release on our website: https://lnkd.in/eJKBfK9Q

Lexeo is excited to join the American Heart Association conference in Chicago, Ill this week, where we are sponsoring an industry symposium: 'Getting to the Heart of the Matter: Gene Therapy for Cardiac Diseases'   On Sunday, 11/17, our Chief Medical Officer and Head of Research, Dr. Eric Adler will join Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford, for a discussion on the potential of gene therapy to target the underlying genetic causes of cardiac diseases and Lexeo’s clinical-stage programs. Additional information on the session can be found at https://lnkd.in/eD8PCAgU

This past weekend, Lexeo was inspired to attend The SADS Foundation (Sudden Arrhythmia Death Syndrome) 2024 International Conference in Chicago, IL. The event brings together patients affected by inherited arrhythmogenic diseases and cardiomyopathies. It provides an opportunity for families to connect with others going through similar challenges and learn about the latest research from top medical experts. Lexeo is proud to sponsor this symposium, furthering our commitment to innovation and excellence in cardiology. Learn more about LX2020, our program targeting PKP2 Arrhythmogenic Cardiomyopathy here: https://lnkd.in/gNWDX9aQ

Last week, the Lexeo team sat down with NeurologyLive to discuss the interim presentation on LX1001, a gene therapy candidate for the treatment of APOE4-associated Alzheimer's disease, at the CTAD Clinical Trials on Alzheimer's Disease Conference.   Our CEO, Nolan Townsend, Chief Medical Officer, Dr. Sandi See Tai and Dr. Kim Johnson from Duke University School of Medicine provided an overview of the interim Phase 1/2 data and the unique opportunity to treat individuals with two copies of the APOE4 allele, who have a significantly higher risk of developing Alzheimer's in their lifetimes.   Click here to watch the full interview: https://lnkd.in/esNQ8KEb

We are excited to announce positive interim data for LX1001, the first-ever gene therapy to impact the underlying genetic cause of APOE4-associated Alzheimer’s disease. Treatment with LX1001 led to dose-dependent increases in protective APOE2 protein expression and improvements in Alzheimer's-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes. LX1001 also demonstrated a favorable safety profile with no reports of ARIA. Data were presented earlier today by Dr. Kim Johnson in a late-breaking oral presentation at the CTAD Clinical Trials on Alzheimer's Disease conference and will be shared in a webcast at 7:00 AM ET. Additional information can be found in our press release: https://lnkd.in/eHeuVbxr